Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
John Oyler
Pharma
BeiGene doubles sales on Brukinsa, tislelizumab strength
While Brukinsa’s blockbuster future now rests on commercial execution, tislelizumab’s path looks more uncertain.
Angus Liu
Feb 27, 2023 10:56am
AZ-Daiichi, Biogen-Eisai, Hutchmed, Junshi—Fierce Pharma Asia
May 6, 2022 11:35am
BeiGene CEO Oyler collects 16% pay bump to $16.7M
May 5, 2022 2:12pm
BeiGene CEO talks flagship US site, stock delisting risk
Apr 29, 2022 7:00am
BeiGene, Novartis' PD-1 tislelizumab posts esophageal cancer win
Jan 28, 2021 10:31am
BeiGene-Novartis, Sinovac and Celltrion—Fierce Pharma Asia
Jan 15, 2021 5:07am